Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer

  • Marcia S Brose1Email author,
  • Christopher M Nutting2,
  • Steven I Sherman3,
  • Young Kee Shong4,
  • Johannes WA Smit5,
  • Gerhard Reike6,
  • John Chung7,
  • Joachim Kalmus6,
  • Christian Kappeler6 and
  • Martin Schlumberger8Email author
BMC Cancer201111:349

DOI: 10.1186/1471-2407-11-349

Received: 23 March 2011

Accepted: 11 August 2011

Published: 11 August 2011

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
23 Mar 2011 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
29 Mar 2011 Author responded Author comments - Martin Schlumberger
Resubmission - Version 3
29 Mar 2011 Submitted Manuscript version 3
24 Jul 2011 Reviewed Reviewer Report - Dirk Vordermark
9 Aug 2011 Author responded Author comments - Martin Schlumberger
Resubmission - Version 4
9 Aug 2011 Submitted Manuscript version 4
Publishing
11 Aug 2011 Editorially accepted
11 Aug 2011 Article published 10.1186/1471-2407-11-349

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Department of Otorhinolaryngology: Head and Neck Surgery, Department of Medicine, Division of Hematology/Oncology, The University of Pennsylvania, Abramson Cancer Center
(2)
Head and Neck Unit, Royal Marsden Hospital
(3)
Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Endocrine Multidisciplinary Center
(4)
Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine
(5)
Department of Medicine, Endocrinology, and Metabolic Diseases, Leiden University Medical Center
(6)
Bayer Schering Pharma AG
(7)
US Medical Sciences, Oncology, Bayer HealthCare Pharmaceuticals
(8)
Institut Gustave Roussy, rue Camille Desmoulins

Advertisement